A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients
Public ClinicalTrials.gov record NCT00969722. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Study of Monoclonal Antibody 3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Compared to 13-cis-Retinoic Acid Plus GM-CSF in High Risk Stage 4, Primary Refractory Neuroblastoma Patients
Study identification
- NCT ID
- NCT00969722
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- United Therapeutics
- Industry
- Enrollment
- 1 participant
Conditions and interventions
Conditions
Interventions
- MAb-3F8 Biological
- Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Biological
- 13-cis-Retinoic Acid Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Months to 13 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2009
- Primary completion
- Jul 31, 2010
- Completion
- Not listed
- Last update posted
- Mar 7, 2013
Started 2009
United States locations
- U.S. sites
- 15
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Phoenix Children's Hospital | Phoenix | Arizona | 85016 | — |
| Rady Children's Hospital of San Diego | San Diego | California | 92123 | — |
| Georgetown Medical Center | Washington D.C. | District of Columbia | 20057 | — |
| All Children's Hospital in Florida | St. Petersburg | Florida | 33701 | — |
| LSU Health Sciences Center; Children's Hospital | New Orleans | Louisiana | 70118 | — |
| Children's Hospitals and Clinics of Minnesota | Minneapolis | Minnesota | 55404 | — |
| Children's Hospital at Montefiore | The Bronx | New York | 10467 | — |
| Duke University Medical Center | Durham | North Carolina | 27705 | — |
| Nationwide Childrens Hospital | Columbus | Ohio | 43205 | — |
| University of Oklahoma Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania | 15224 | — |
| US Oncology | Dallas | Texas | 75230 | — |
| The University of Texas M.D. Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Utah Medical Center | Salt Lake City | Utah | 84113 | — |
| Vermont Cancer Center | Burlington | Vermont | 05405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00969722, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 7, 2013 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00969722 live on ClinicalTrials.gov.